Back to Newsroom

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, announced today the appointment of Glenn Prestwich, Ph.D., as Executive Vice President of Chemistry. Dr. Prestwich, Presidential Professor of Medicinal Chemistry at the University of Utah and former member of the Symic Bio Scientific Advisory Board, will assume a direct executive role in the advancement of the company’s platform of clinical-stage therapeutics and in the expansion of its pipeline.
READ MORE…